Processa pharmaceuticals appoints life sciences industry veteran george ng as chief executive officer

Hanover, md, aug. 08, 2023 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces today that industry veteran george ng has been appointed to serve as the company's chief executive officer and as a board director as of august 8, 2023. dr. david young will focus his efforts on the development of the next generation chemotherapy (ngc) drugs as president of research and development and as a board member.
PCSA Ratings Summary
PCSA Quant Ranking